Literature DB >> 9166860

Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups.

D Turbay1, J Lieberman, C A Alper, J C Delgado, D Corzo, J J Yunis, E J Yunis.   

Abstract

Genes of the major histocompatibility complex (MHC) are associated with susceptibility to different immune and nonimmune mediated diseases. We had reported that the drug adverse reaction, clozapine-induced agranulocytosis (CA), is associated with different HLA types and HSP70 variants in Ashkenazi Jewish and non-Jewish patients, suggesting that a gene within the MHC region is associated with CA. This study was designed to find common genetic markers for this disorder in both ethnic groups. The tumor necrosis factor (TNF) microsatellites d3 and b4 were found in higher frequencies in both Jewish and non-Jewish patients: 51 of 66 (77%) and 48 of 66 (57%), respectively. Comparisons of these frequencies with those of controls, 28 of 66 (42%) and 18 of 66 (27%), were statistically significant (corrected P value = .001 for the d3 allele and .0005 for the b4 allele). On the other hand, the TNF microsatellite b5 was underrepresented in the group of patients, 9 of 66 (14%), when compared with the control subjects, 43 of 66 (65%) (corrected P value = .0005), probably related to protection from CA. Our results show a strong association of some genetic variants of the TNF loci with susceptibility to CA in two different ethnic groups suggesting involvement of TNF and/or associated gene(s) products in the pathogenesis of this hematologic-drug adverse reaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166860

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

Review 2.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

3.  Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.

Authors:  K van der Weide; H Loovers; K Pondman; J Bogers; T van der Straaten; E Langemeijer; D Cohen; J Commandeur; J van der Weide
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

Review 4.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 5.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 6.  Genetic predictors of therapeutic response to clozapine: current status of research.

Authors:  Dalu Mancama; Maria J Arranz; Robert W Kerwin
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 7.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

Review 8.  More than 25 years of genetic studies of clozapine-induced agranulocytosis.

Authors:  S A J de With; S L Pulit; W G Staal; R S Kahn; R A Ophoff
Journal:  Pharmacogenomics J       Date:  2017-04-18       Impact factor: 3.550

9.  Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter.

Authors:  A M Uglialoro; D Turbay; P A Pesavento; J C Delgado; F E McKenzie; J G Gribben; D Hartl; E J Yunis; A E Goldfeld
Journal:  Tissue Antigens       Date:  1998-10

10.  Clozapine-induced blood dyscrasias in Saudi Arab patients.

Authors:  Norah O Abanmy; Afnan Al-Jaloud; Aisha Al-Jabr; Rana Al-Ruwaisan; Walaa Al-Saeed; Solafa Fatani
Journal:  Int J Clin Pharm       Date:  2014-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.